Genzyme troubled by new contamination problems at manufacturing plant
This article was originally published in Scrip
Genzyme has been hit with more contamination problems at its Allston, Massachusetts, manufacturing plant, this time involving foreign particle contamination of five of its products – Cerezyme, Fabrazyme, Myozyme, Thyrogen and Aldurazyme – which are used to treat rare, serious, and life-threatening diseases.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.